Worth reading
37Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
176
Millions of yen (year-on-year deterioration in net income for the period)Wording
Conditional
How definitive the wording is.Contents of this document
Presentation materials for financial resultsFirst quarter of the fiscal year ending December 20265 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Operating profit¥-122 million
Ordinary income¥-120 million
Net income¥-256 million
Selling, general and administrative expenses¥72 million
Results for the three months of the current quarterBusiness revenue of ¥17 million, business expenses of ¥139 million, operating loss of ¥122 million, ordinary loss of ¥120 million, and net loss for the period of ¥256 million
Full-year earnings forecast
Business profitability
¥682 million
Net income for the current fiscal year
¥-567 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Decrease in business revenue-¥6 million
- Increase in business expenses¥34 million
- Deterioration in operating profit-¥41 million
- Deterioration in ordinary profit-¥40 million
- Deterioration in net income for the period-¥176 million
- Impairment Losses¥135 million
New initiatives
- Execution of a memorandum of understanding and contract discussions concerning joint exploratory research with SpiroChem on mRNA-targeting compounds
- Launch of Perfusio commercialization activities, consultation with PMDA, and selection of partner companies
- Preparation for animal studies of in-house Pipeline 1
- Preparation for filing a patent for the drug candidate in in-house Pipeline 2
- Relocation to the Kawasaki Research Institute and preparations for full-scale operations
Key KPIsA metric the company considers important as a management benchmark.
- Target number of new contracts signed2 Engagements
- Number of companies with executed CDAs under contract negotiations8 companies
- Target number of in-house pipeline programs2 bottles
- Target year for starting Perfusio sales2,027 Year
Market Size / Share
The presentation states that approximately 300,000 people worldwide and approximately 10,000 people in Japan have ALS. No market size or market share information was disclosedNumber of stores and locations
The relocation of 1 research facility was completed in March 2026. The number of facilities opened or closed during the period was Not disclosed| Item | Details |
|---|---|
| Document type | Presentation materials for financial results |
| Fiscal Period Covered | First quarter of the fiscal year ending December 2026 |
| Operating profit | ¥-122 million |
| Ordinary income | ¥-120 million |
| Net income | ¥-256 million |
| Selling, general and administrative expenses | ¥72 million |
| Results for the three months of the current quarter | Business revenue of ¥17 million, business expenses of ¥139 million, operating loss of ¥122 million, ordinary loss of ¥120 million, and net loss for the period of ¥256 million |
| Full-year earnings forecast | Business profitability ¥682 million / Net income for the current fiscal year ¥-567 million |
| Breakdown of Factors Affecting the Change | Factors Decrease in business revenue / Amount -¥6 million, Factors Increase in business expenses / Amount ¥34 million, Factors Deterioration in operating profit / Amount -¥41 million, Factors Deterioration in ordinary profit / Amount -¥40 million, Factors Deterioration in net income for the period / Amount -¥176 million, Factors Impairment Losses / Amount ¥135 million |
| Key KPIs | Indicator name Target number of new contracts signed / Value 2 Engagements, Indicator name Number of companies with executed CDAs under contract negotiations / Value 8 companies, Indicator name Target number of in-house pipeline programs / Value 2 bottles, Indicator name Target year for starting Perfusio sales / Value 2,027 Year |
| Number of stores and locations | The relocation of 1 research facility was completed in March 2026. The number of facilities opened or closed during the period was Not disclosed |
| Market Size / Share | The presentation states that approximately 300,000 people worldwide and approximately 10,000 people in Japan have ALS. No market size or market share information was disclosed |
| New initiatives | Execution of a memorandum of understanding and contract discussions concerning joint exploratory research with SpiroChem on mRNA-targeting compounds, Launch of Perfusio commercialization activities, consultation with PMDA, and selection of partner companies, Preparation for animal studies of in-house Pipeline 1, Preparation for filing a patent for the drug candidate in in-house Pipeline 2, Relocation to the Kawasaki Research Institute and preparations for full-scale operations |
Items this document does not state (18)
Net SalesGross Profit MarginOperating profit marginProgress against full-year forecastSelf-assessment against the planSegment resultsUnit price and quantity metricsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Business expenses increased by ¥34 million year on year, including ¥67 million in research and development expenses and ¥72 million in selling, general and administrative expenses. In addition, an impairment loss of ¥135 million on property, plant and equipment was recognized as an extraordinary loss.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.